Introduction
In 2007, there were an estimated 33 million people
living with HIV, and sub-Saharan Africa accounted for
67% of all people with HIV and 75% of all AIDS deaths
[1]. The prevalence of HIV in the sub-Saharan Africa
region is 6% [2]. Although the number of new infections worldwide has stabilized since 2000, the number
of people living with HIV has increased because of HIV
treatments that are extending survival [1]. Antiretroviral therapy (ART) is becoming more readily available
across sub-Saharan Africa, but the nutritional situation, which was already poor, is worsening further for
certain vulnerable populations in the face of the global
economic crisis [3].
Malnutrition occurs in various forms, including
undernutrition (low weight, short stature, micronutrient deficiencies, low birthweight, and suboptimal
breastfeeding practices) as well as overweight and
obesity. Overweight or obesity may actually co-occur
with micronutrient deficiencies in the same person.
For HIV and other infections, low body weight, weight
loss, micronutrient deficiencies, and deficiencies of
other nutrients that affect the immune system are
Food and Nutrition Bulletin, vol. 31, no. 4 (supplement) 2010, The United Nations University.
S313
S314
Micronutrients
Micronutrients are important for immunity, growth,
and psychomotor development, because they catalyze
many processes in the body and are essential components of specific tissues. For example, iron is part of
hemoglobin, which transports oxygen in the body;
vitamin A is known as the anti-infective vitamin,
and a high dose is provided every 6 months to young
children as a child survival intervention; zinc tablets
are recommended as adjunct treatment for children
suffering from diarrhea in order to cure the episode
faster and reduce the risk of a next episode. Because
of the essential role of micronutrients in supporting
the bodys functions, HIV-infected people very much
need to have an adequate micronutrient status. In this
section we will review:
To what extent micronutrient deficiencies occur
among HIV-infected people, as indicated by inadequate dietary intake or as directly measured by low
micronutrient status (i.e., low levels in the body)
from biochemical and other measurements;
Whether HIV-infected people have higher micronutrient needs than non-HIV-infected people;
How micronutrient deficiencies affect HIV
infection.
Prevalence of micronutrient deficiencies among HIVinfected people
Main points
Micronutrient intake. Low intakes of many different micronutrients have been reported in different
groups of HIV-infected adults [1017]. Many studies
have reported that a large proportion of HIV-infected
adults consume less than the Recommended Dietary
Allowance (RDA) of many individual micronutrients,
including vitamin A, vitamin C, vitamin E, thiamine,
riboflavin, vitamin B6, folate, iron, and zinc. The RDA*
is the level of intake of a nutrient that is considered to
S315
S316
Micronutrient
Low intake
described in
literature
Deficient
status
described
Vitamin A, g
Vitamin E, mg
Vitamin B1, mg
Vitamin B2, mg
Niacin, mg
Pantothenic acid, mg
Folic acid, g
Vitamin C, mg
Vitamin B6, mg
Vitamin B12, g
Calcium, mg
Magnesium, mg
Selenium, g
Zinc, mg
Iron, mg
Iodine, g
Copper, mg
Phosphorus, mg
Potassium, mg
Manganese, mg
Vitamin D, g
Vitamin K, g
Biotin, g
Sodium, mg
Chromium, g
Molybdenum, g
Chloride, mg
Carotenoids, g
X
X
X
X
X
X
X
X
Yes
Yes
X
X
X
Yes
Yes
15
15
150
2
1,000
3,500
5
30
Yes
S317
levels were associated with greater HIV disease progression [39, 79]. Serum or plasma zinc concentrations must be interpreted with caution in patients with
inflammation, as zinc is a negative acute phase reactant
in blood.
Low serum or plasma selenium concentrations have
been associated with accelerated progression of HIV
disease among adults [80] and pregnant women in
Tanzania [81] and with higher mortality among HIVinfected adults [82], HIV-infected children [83], and
children born to HIV-infected mothers in Tanzania
[84]. Low plasma selenium concentrations were associated with higher mother-to-child transmission of HIV
through the intrapartum route [85]. Selenium deficiency was associated with a higher risk of genital shedding of HIV in HIV-infected women in Kenya [86].
HIV-infected injection drug users with low serum selenium concentrations were at high risk for developing
mycobacterial disease over a 2-year period [87]. Low
plasma selenium concentrations have been described
in HIV-infected adults with myopathy (disease of the
muscle) compared with those in HIV-infected adults,
matched by CD4 lymphocyte count, who did not have
myopathy [88].
Table 1 summarizes micronutrients for which an
association between a low status and poor disease
outcome has been documented.
Comments
S318
Evidence
Loss of appetite
Poverty, food insecurity
Difficulty swallowing
Avoiding diarrhea
Malnutrition:
Low BMI
Weight loss
Affecting progression
and outcome
Micronutrient deficiencies
Altered metabolism:
Context in resource-limited settings:
Preexisting malnutrition, food insecurity,
low dietary quality
Risk behavior
S319
S320
High-dose vitamin A supplementation of HIV-positive children under 5 years of age has been shown
to reduce morbidity and mortality
Vitamin A supplementation of mothers (10,000
IU/day during pregnancy or a single high dose of
400,000 IU after delivery) does not seem to reduce
mother-to-child HIV transmission.
An adverse effect of supplementation during pregnancy and lactation on mother-to-child transmission was observed when vitamin A (5,000 IU/
day) was combined with high-doses of -carotene
(30 mg/day). It is unknown whether this effect is due
to -carotene, vitamin A, or both.
The outcomes of supplementation with single nutrients (vitamin E, selenium, zinc, and iron) are not yet
conclusive.
S321
S322
S323
In principle, the aim of nutrition interventions for HIVinfected people is straightforward: to reduce mortality
risk by increasing or maintaining body weight (i.e.,
preventing, halting, or recovering weight loss) and to
support the immune system and body performance
by providing access to adequate nutrition in conjunction with infection control. However, because weight
loss is affected by many interrelated factors (as shown
in fig. 2), it is more complex than one might initially
think. Also, management of weight and nutritional
status becomes more and more complex as HIV infection progresses. Therefore, nutrition interventions
should start as early as possible and should include
nutrition assessment, education, and counseling, augmented with supplements and pharmaceutical preparations when required.
Here, we will first review the management of weight
loss in settings where access to food and to ART
is not constrained, followed by a review of current
recommendations and practices in resource-limited
settings, and then review studies that provided food
supplements, both in resource-limited and in resourceadequate settings, in order to assess how these results
can inform HIV care and treatment in resourceconstrained settings.
Current recommendations and practice in resourceadequate settings
Main points
S324
TABLE 3. Nutrient composition of a variety of food supplements provided to HIV patients suffering from malnutrition, and
Composition per 100 gof product
Ingredient
Total quantity, g (or mL)
Energy, kcal
Protein, g
Fat, g
Micronutrients
Vitamin A, g
Vitamin E, mg
Vitamin B1, mg
Vitamin B2, mg
Niacin, mg
Pantothenic acid, mg
Folic acid, g
Vitamin C, mg
Vitamin B6, mg
Vitamin B12, g
Calcium, mg
Magnesium, mg
Selenium, g
Zinc, mg
Iron, mg
Iodine, g
Copper, mg
Phosphorus, mg
Potassium, mg
Manganese, mg
Vitamin D, g
Vitamin K, g
Biotin, g
Sodium, mg
Chromium, g
Molybdenum, g
Chloride, mg
Ensure
Plus (mL)
Plumpy
nut
Supplementary
Plumpy
RUFValid
RUFS-PPB
CSB
CSBUSDA
100
151
5.7
4.7
100.0
543.5
13.6
35.8
100.0
543.5
13.6
35.8
100
536.2
12.3
> 35
100.0
555.1
14.5
37.1
100.0
363.6
13.4
7.0
100.0
376.0
17.2
6.9
160
1.2
0.138
0.18
2.55
0.74
26
6.4
0.21
0.21
128
27.7
5.5
1.7
1.62
17
0.21
117
170
0.55
0.64
913.0
20.0
0.6
1.8
5.3
3.1
209.8
53.3
0.6
1.8
300.0
92.0
30.0
14.0
11.5
100.0
1.7
300.0
1,110.9
913.0
20.0
0.6
1.8
5.3
3.1
209.8
53.3
0.6
1.8
300.0
92.0
30.0
14.0
11.5
100.0
1.7
300.0
555.4
816.9
18.2
0.6
1.7
4.8
2.8
191.7
48.3
0.5
1.6
304.1
289.8
21.2
0.4
0.5
5.7
278.1
8.7
0.3
0.2
3.5
12.4
10.5
92.7
1.7
351
935.6
163.3
36.7
0.5
0.6
338.8
98.0
31.8
3.3
3.3
40.9
7.0
0.3
0.1
69.0
133.7
5.9
2.1
4.3
0.4
285.7
1,175.5
0.8
280.7
454.5
16.3
21.0
65.2
16.3
21.0
14.6
2.0
1.6
871.0
8.7
0.5
0.5
6.2
3.4
179.6
40.0
0.5
1.0
831.0
173.8
6.0
5.0
17.5
57.0
0.9
206.0
634.0
0.7
4.9
7.3
15
106
4.7
12
115
59.5
RNI
2,600
48
600
10
1.4
1.6
18
6
400
75
2
6
1,000
15
15
150
2
1,000
3,500
5
30
CSB, corn-soya blend; RNI, recommended nutrient intake; RUF, ready-to-use food; RUFS, ready-to-use fortified spread; UL 19-70, upper
limit for adults aged 19 to 70 years
a. Ensure Plus is a commercial product that was used by Berneis et al. [175]. Supplementary Plumpy and Plumpynut are commercial products
produced by Nutriset France for treating moderate and severe malnutrition, respectively, and their composition is comparable to that of
S325
the absolute amount of nutrients provided by these foods when providing 1,600 kcal/daya
Intake when 1,600 kcalof product is consumed
Supplementary
Plumpy,
92 g
RUF-Valid RUFS-PPB
For 1,600
kcal
Ensure
Plus
Plumpy
nut, 92 g
1,600
30
1,060.0
1,600.6
60.4
49.8
294.4
1,600.0
40.0
105.3
294.4
1,600.0
40.0
105.3
298.0
1,597.9
36.7
> 35
1,696.0
12.7
1.5
1.9
27.0
7.8
275.6
67.8
2.2
2.2
1,356.8
293.6
58.3
18.0
17.2
180.2
2.2
1,240.2
1,802.0
5.8
6.8
2,688.0
58.9
1.8
5.3
15.6
9.1
617.6
156.8
1.8
5.4
883.2
270.7
88.3
41.3
33.9
294.4
5.1
883.2
3,270.4
2,688.0
58.9
1.8
5.3
15.6
9.1
617.6
156.8
1.8
5.4
883.2
270.7
88.3
41.3
33.9
294.4
5.1
883.2
1,635.2
2,434.4
54.2
1.8
5.1
14.3
8.3
571.3
143.9
1.5
4.8
906.2
48.0
61.8
192.0
48.0
61.8
192.0
600
10
1.4
1.6
18
6
400
75
2
6
1,000
15
15
150
2
1,000
3,500
5
30
159.0
1,123.6
49.8
127.2
1,219.0
CSB
CSBUSDA
289.1
1,604.8
41.9
107.4
441.3
1,604.8
59.0
30.9
426.0
1,601.8
73.3
29.4
837.8
61.4
1.3
1.5
16.5
1,227.2
38.4
1.5
0.9
15.3
37.0
31.3
276.2
5.1
1,046.0
2,788.1
472.0
106.2
1.5
1.7
979.4
283.2
92.0
9.4
9.4
180.5
30.7
1.2
0.6
304.4
590.0
26.0
9.4
18.9
1.1
826.0
3,398.4
3.4
1,239.0
2,006.0
43.5
5.9
7.1
3,710.5
37.1
2.3
2.0
26.5
14.5
765.1
170.4
2.1
4.3
3,540.1
740.4
25.6
21.3
74.5
242.8
3.8
877.6
2,700.8
3.0
20.9
177.3
UL
19-70
3,000
1,000
35
600
1,000
100
400
45
45
1,100
10
50
31.1
F100. RUF-Valid is the fortified spread used in the study by Bahwere et al. [197]. RUFS-PPB refers to the product used
by Ndekha and colleagues [196, 207] and van Oosterhout et al. [208]. CSB is the product used by the latter investigators. CSB-USDA refers to the content of the CSB donated by the US Agency for International Development (USAID).
concluded that the impact of anabolic steroids in HIVinfected people is limited and that side effects include
liver dysfunction and hypogonadism [177]. Moreover,
their use in women is currently not recommended.
Growth hormone increases lean body mass in HIVinfected patients with wasting and promotes lean tissue
retention in those with secondary infections. However,
side effects include increased blood glucose, arthralgia,
myalgia, and peripheral edema [178]. Therefore, the
use of growth hormone should be carefully considered
and monitored.
Because micronutrient deficiencies also reduce
appetite, it will be worth assessing whether micronutrient supplements increase appetite among HIV patients
in resource-limited settings and hence contribute to
reversing weight loss. Adults in a refugee camp in
Kenya reported an increased appetite when using
a micronutrient powder (World Food Programme,
unpublished observation). The micronutrient powder
for home fortification is distributed to all people in
the camps aged 6 months and older and contains 16
micronutrients at a level of 1 RNI for 1- to 3-yearold children, but with reduced iron and zinc content
because of malaria endemicity. Improved appetite was
S326
Weight gain
S327
Pre-existing malnutrition complicates the formulation of appropriate dietary advice (prevention and
treatment of malnutrition at the same time), and
food insecurity limits the extent to which dietary
advice can be implemented.
There are no specific guidelines for treating malnutrition in HIV-infected adults. WHO guidelines for
treating wasted adults are used instead.
It is worth assessing whether micronutrient supplementation in resource-limited settings stimulates
appetite among HIV-infected people suffering from
anorexia.
It is not known whether the upper limits for intake
of micronutrients for adults in general are also safe
for HIV-infected people, who may also be malnourished, but the current practice of using RUTF with
a composition comparable to that of F100 suggests
that it is assumed safe.
Evidence
Dietary advice and constraints in resource-limited settings. The way in which weight loss has been managed
in resource-adequate settings shows that it is a complex
matter, requiring more than just an adequate diet,
which in itself is already difficult for many people in
resource-limited settings. Furthermore, particularly
in the context of HIV infection, experts do not agree
entirely on what constitutes optimal nutrition or on
how it is best provided [187]. The latter is also due
to the fact that evidence on the impact of nutrition
interventions among HIV-infected people is scanty.
However, the authors are of the opinion that the lack of
evidence is also related to difficulties with conceptualizing the relationship and appropriately designing and
interpreting macronutrient intervention studies.
Since nutrition among people in developing countries is also closely related to food security and poverty,
nutrition interventions for HIV-infected people in
developing countries include nutrition assessment,
education, and counseling, targeted nutrition supplements, and establishing linkages with food security and
livelihood programs [188, 189]. Many patients already
suffer from malnutrition before HIV-related weight
loss and wasting occur.
Dietary guidelines from WHO for HIV-infected
people are summarized in table 4 [187, 190, 191], and
several documents provide guidance [187, 190194].
According to these guidelines, HIV-infected people
should consume the same proportions of energy from
protein (12% to 15%), fat, and carbohydrates as are
recommended for people who do not have HIV infection; increase total energy intake of adults by 10% to
30%, depending on clinical status; and consume 1
Recommended Nutrient Intake (RNI) of each required
vitamin and mineral. However, there are no established therapeutic guidelines for the management of
weight loss and wasting in HIV-infected patients. The
S328
TABLE 4. WHO guidance for nutritional management of HIV infection and malnutrition among adults
With regard to nutrition assessment
Measure weight, weight change, height, BMI, MUAC
Assess appetite, difficulty swallowing, nausea, diarrhea, drugfood interaction effects
Assess household food security
With regard to malnutrition
Mild to moderately malnourished adults (BMI < 18.5 kg/m2), regardless of HIV status, should receive supplementary
feeding. Usually, fortified blended foods, such as CSB, are provided, but compressed bars or biscuits and lipid-based
nutrient supplements (pastes) may also be used
Severely malnourished adults (BMI < 16 kg/m2) should receive a therapeutic food, nutritionally equivalent to F100.
For initial treatment of severely malnourished adults aged 19 to 75 years, energy intake should be 40 kcal/kg/day; for
initial treatment of those aged 15 to 18 years, energy intake should be 50 kcal/kg/day [212]
With regard to dietary intake [191, 194]
Energy intake in asymptomatic HIV infection should be increased by 10%
During infection, the aim should be to reach the maximum achievable intake of 20% to 30% above normal intake;
during the recovery phase, intake should be increased to the maximum extent possible
Percentage of energy from protein and from fat should not be changed compared with that for persons in the HIVnegative state.
However, as energy intake is increased, the absolute amounts of protein and fat are also increased
Intake of 1 RNI of vitamins and minerals is recommended, even though this may not be enough to correct nutritional
deficiencies in HIV-infected people, but the lack of safe upper limits for HIV-infected people precludes recommending higher intakes
BMI, body mass index; CSB, cornsoya blend; MUAC, mid-upper-arm circumference; RNI, recommended nutrient intake
Source: World Health Organization [187].
S329
In principle, HIV infection does not require different treatment in resource-limited settings. However,
a higher prevalence of malnutrition, later detection
of the infection, and limited resources present many
different challenges that are unique to the management of HIV infection in resource-limited settings.
Lack of evidence for the applicability of both the
RNIs and ULs of intake for HIV-infected people,
who may also suffer from some degree of malnutrition, means that intake levels and guidance for nonHIV-infected people, with or without moderate or
severe malnutrition, are also applied to HIV-infected
people.
Impact of food supplements
S330
FIG. 5. Factors affecting the impact of a food intervention on malnutrition and HIV disease outcome
S331
S332
life were also not different. The reasons for the greater
improvement in nutritional status in the RUFS group
may be the composition of the supplement (higher
energy density and higher nutritional value) and its
use (it may have been shared less because it was readyto-eat). In another paper [207], the authors assessed
the outcome among the same patients 3 and 9 months
after the 3.5-month supplementation period ended.
At 3 months, the BMI did not differ between the two
groups (n = 162 and n = 174 in the RUFS and the control group, respectively); at 12 months, the 0.5 kg/m2
difference that was observed at the end of the supplementation period (19.0 vs. 18.5 kg/m2, respectively;
p = .001) was observed again (20.3 vs. 19.8 kg/m2,
respectively; p = .22), but due to greater variation, the
difference was not significant any more. The authors
also compared their results after 3.5 months of food
supplementation and 3 months later with historical
data from patients who received ART but no food supplements [208]. They concluded that patients receiving
RUFS or CSB during ART had improved nutritional
recovery (increased BMI after 14 weeks) as compared
with those receiving no food supplement, and that the
effect was superior with RUFS. However, the food supplementation was stopped at 14 weeks, and at 26 weeks
the significant difference in BMI no longer existed.
The authors suggested that longer supplementation
with food might have been required by these patients.
There was no difference with regard to hospitalizations
and survival, but the groups involved in the study were
small (n = 104 for no food supplement, n = 244 for
RUFS, and n = 245 for CSB). As was also found in the
study by Cantrell et al. [205], treatment adherence was
better in the groups receiving supplements than in the
group not receiving supplement (< 1% in the supplemented groups vs. 9% in the nonsupplemented group
stopped ART after 24 weeks).
Preliminary results of a randomized trial in Kenya
that provided either nutrition counseling or nutrition
counseling and enhanced CSB (with additional whey
powder, oil, sugar, and adjusted micronutrient premix)
to patients receiving ART as well as to patients before
the initiation of ART found that BMI increased in
all groups, but more among those that also received
enhanced CSB.** The difference between groups receiving and those not receiving enhanced CSB was larger
among the pre-ART clients, and BMI improvement
was larger among people enrolled while on ART than
among the pre-ART clients. Six months after enrollment, approximately 45% of the clients in the CSB
group and approximately 55% in the nutrition counseling group were lost to follow-up (status unknown).
** Unpublished observations from FANTA and the Kenya
Medical Research Institute (KEMRI), presented at the
International Conference of Nutrition in Bangkok, October
2009.
S333
energy intake.
The zinc and iron contents of one of the spreads
(RUFS-PPB) were adjusted to be comparable to those
of the CSB used in their study [196, 207, 208], and
their levels were hence more comparable to the RNIs.
On the basis of the available studies, it appears that in
settings of high food insecurity, RUFS results in faster
weight gain than CSB when provided to malnourished
adults who have developed AIDS. This finding is
consistent with findings among moderately wasted
children [210] and may be due both to the composition
of the food (variety, quality, and relative proportions
of macro- and micronutrients; higher energy density;
and lower content of antinutrients) and to its use (less
likely to be shared with other family members because
it is ready to eat and more easily accepted as being a
therapeutic food to be consumed exclusively by the
patient). This faster improvement of nutritional status
may be particularly of value among severely to moderately malnourished patients who are at increased risk
for death. However, the cost of the spreads is approximately three times higher than that of an FBF providing the same amount of energy, and it will therefore be
worthwhile to assess whether it is possible to sustain
the weight rapidly regained during a few months of
RUFS consumption by continuing supplementation
with an FBF, and to calculate the cost-effectiveness of
first using RUFS rather than FBF.
As mentioned before, nutrition education should
always be part of HIV infection control. Furthermore,
the composition of the diet and the nutritional status
of the patient and its changes during treatment should
guide the selection of a food supplement, if any.
Extrapolating results from studies conducted in one
setting to another setting. The design of studies using
food supplements varies widely, not only with regard
to the supplements used, but also the characteristics
of the patients (HIV stage, nutritional status, age, sex,
physiological status), the ART and other treatment they
receive, and their basic diet. All these factors need to
be taken into account when interpreting results and
when considering the applicability of results of studies
with particular foods conducted in a certain context
to a different group of HIV-infected people in another
context.
Particular caution is necessary when extrapolating
from studies conducted in resource-adequate settings
and applying them to resource-limited settings [211].
In general, the impact of a nutritional intervention
depends on nutritional status at the start, which is usually much better among patients in resource-adequate
settings than among patients in resource-limited settings. In resource-adequate settings, the largest groups
at risk for HIV are injection drug users and men
having sex with men (MSM). This situation is different
from that in sub-Saharan Africa, where HIV affects
men, women, and children. The medication taken
S334
Discussion
The main points at the start of each subsection have
summarized currently available evidence and, where
available, current consensus. Here, we discuss the two
different conceptual approaches to the relationship
between nutrition and HIV infection and how this
affects the way evidence is gathered and interpreted
and programs in resource-limited settings are designed,
and we identify questions that need to be resolved
urgently.
The Academy of Sciences of South Africa stated in
its 2007 report It is clear that malnutrition per se is
a condition that impacts negatively on health on so
many levels that a justification to feed malnourished
people on the basis of their increased risk of any single
disease is only a small part of the rationale [201].
This statement highlights very well the two different
concepts that are being applied to nutrition in HIV/
AIDS, a medical point of view versus a more holistic,
humanitarian assistance point of view.
The medical approach examines the impact on
disease outcome of specific (micro)nutrient supplements according to the same methodology that is
used to assess the impact of medication and treatment
protocols, i.e., comparing the results obtained in the
intervention group with those obtained in a group that
receives an otherwise unchanged diet or a placebo supplement. Because of the inclusion of a group receiving
placebo or otherwise unchanged diet for comparison,
these trials usually use highly specific supplements that
provide only a limited amount of energy. Experts favoring a more holistic, humanitarian assistance point of
view treat malnutrition with an energy- and nutrientrich food because of the many negative consequences
of malnutrition for health and not primarily because
of how this affects the outcome of a specific disease,
such as HIV. However, detailed knowledge of nutrition
and its interaction with HIV infection is required in
order to treat malnutrition in the most effective way,
affecting both outcomes. Furthermore, because treating
malnutrition and providing food supplements is part of
the individual medical treatment plan for HIV infection, and most financing for HIV programs aims to
improve HIV disease control and outcome, the benefit
of nutritional support for HIV disease outcome needs
to be clear.
However, as mentioned in the section HIV infection and nutrition review of nutrition interventions
gathering evidence of the impact of food interventions
using the same approach as that used for medication
is not possible, because there is no placebo for macronutrient supplements, and the net intervention is the
actual change of the patients diet due to the receipt
of the food supplement but not equal to the nutrient
content of the supplement. This change of diet is highly
S335
S336
Conclusions
The relationship between infection and nutrition has
been known since the early 1900s, but the role of nutrition in medical practice and public health has changed
over time [8]. With the advancement of antibiotics and
pharmaceutical treatment, and the improvement of
diet and nutrition due to improvements in agriculture
and standards of living, attention to the role of nutrition in developed countries dwindled. However, the
role of nutrition in infection was not forgotten, and it
truly resurfaced in the 1980s and 1990s when its role
in reducing child mortality in developing countries
was recognized and emphasized [8, 9]. Thus, the
role of nutrition in health and disease is now widely
acknowledged and its importance for HIV infection
control recognized. However, proving its worth at different stages of HIV infection and under widely varying
circumstances, and deciding what nutrition to provide,
when, and to whom, remains very challenging.
Treating malnutrition, including micronutrient
malnutrition, in HIV infection is more complicated
than preventing a deterioration of nutritional status,
and preventing a deterioration of nutritional status
also slows progression of disease. Therefore, nutrition
assessment, education, and counseling should start
immediately after the diagnosis of HIV infection.
Whether the nutrition advice can be put into practice,
however, depends on availability of and access to food,
including animal-source and plant-source foods.
Where ingredients for a balanced diet are not available or accessible due to food insecurity and poverty,
provision of food supplements may be considered.
Providing cash or other livelihood support can also be
considered, but it is important that this results not only
Acknowledgments
We thank the following people for their input and
review: Martin Bloem, Nils Grede, Tony Castleman,
Andrew Thorne-Lyman, Mark Manary, Eduardo Villamor, Pamela Fergusson, Ian Darnton-Hill, Annmarie
Isler, Francesca Erdelmann, Tina van den Briel, Mutinta
Hambayi, Mary Njoroge, and Joris van Hees.
References
1. Joint United Nations Programme on HIV/AIDS
(UNAIDS). 2008 Report on the global AIDS/HIV epidemic. Geneva: UNAIDS, 2008.
2. Quinn TC. HIV epidemiology and the effects of
antiviral therapy on long-term consequences. AIDS
2008;22(suppl 3):S712.
3. Sztam KA, Fawzi WW, Duggan C. Macronutrient supplementation and food prices in HIV treatment. J Nutr
2010;140:21323.
4. Victora CG, Adair L, Fall C, Hallal P, Martorell R, Richter L, Sachdev HS. Maternal and child undernutrition:
consequences for adult health and human capital. Lancet
2008;371:34057.
5. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J
Nutr 1999;81:1819.
6. Semba RD, Darnton-Hill I, de Pee S. Addressing tuberculosis in the context of malnutrition and HIV coinfection. Food Nutr Bull 2010;31(Suppl):S345S364.
7. Frega R, Duffy F, Rawat R, Grede N. Food insecurity in the context of HIV/AIDS: a framework
for a new era of programming. Food Nutr Bull
2010;31(Suppl):S292S312.
8. Semba RD. Nutrition and development: a historical
perspective. In: Semba RD, Bloem MW, eds. Nutrition
and health in developing countries, 2nd ed. Totowa, NJ,
USA: Humana Press, 2008:131.
9. Schroeder DG. Malnutrition. In: Semba RD, Bloem MW,
eds. Nutrition and health in developing countries, 2nd
ed. Totowa, NJ, USA: Humana Press, 2008:34176.
10. Abrams B, Duncan D, Hertz-Picciotto I. A prospective
study of dietary intake and acquired immune deficiency
syndrome in HIV-seropositive homosexual men. J
Acquir Immune Defic Syndr 1993;6:94958.
11. Tang AM, Graham NMH, Kirby AJ, McCall AD, Willett WC, Saah AJ. Dietary micronutrient intake and risk
progression to acquired immunodeficiency syndrome
(AIDS) in human immunodeficiency virus type 1
S337
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
S338
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
2007;27:116.
59. Semba RD, Shah N, Strathdee SA, Vlahov D. High
prevalence of iron deficiency and anemia among female
injection drug users with and without HIV infection. J
Acquir Immune Defic Syndr 2002;29:1424.
60. Dancheck B, Tang AM, Thomas AM, Smit E, Vlahov D,
Semba RD. Injection drug use is an independent risk
factor for iron deficiency and iron deficiency anemia
among HIV-seropositive and HIV-seronegative women.
J Acquir Immune Defic Syndr 2005;40:198201.
61. Semba RD, Kumwenda N, Hoover DR, Taha TE,
Mtimavalye L, Broadhead R, Eisinger W, Miotti PG,
Chiphangwi JD. Assessment of iron status using plasma
transferrin receptor in pregnant women with and without human immunodeficiency virus in Malawi. Eur J
Clin Nutr 2000;54:8727.
62. Semba RD, Taha TE, Kumwenda N, Mtimavalye L,
Broadhead R, Miotti PG, Chiphangwi JD. Iron status
and indicators of human immunodeficiency virus disease severity among pregnant women in Malawi. Clin
Infect Dis 2001;32:14969.
63. Antelman G, Msamanga GI, Spiegelman D, Urassa EJ,
Narh R, Hunter DJ, Fawzi WW. Nutritional factors and
infectious disease contribute to anemia among pregnant
women with human immunodeficiency virus in Tanzania. J Nutr 2000;130:19507.
64. Kupka R, Msamanga GI, Mugusi F, Petraro P, Hunter
DJ, Fawzi WW. Iron status is an important cause of
anemia in HIV-infected Tanzanian women but is not
related to accelerated HIV disease progression. J Nutr
2007;137:231723.
65. Dworkin BM, Rosenthal WS, Wormser GP, Weiss
L. Selenium deficiency in the acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr
1986;10:4057.
66. Mantero-Atienza E, Beach RS, Gavancho MC, Morgan
R, Shor-Posner G, Fordyce-Baum MK. Selenium status
of HIV-1 infected individuals. JPEN J Parenter Enteral
Nutr 1991;15:6934.
67. Semba RD, Miotti PG, Chiphangwi JD, Liomba G,
Yang LP, Saah AJ, Dallabetta GA, Hoover DR. Infant
mortality and maternal vitamin A deficiency during
human immunodeficiency virus infection. Clin Infect
Dis 1995;21:96672.
68. Semba RD, Miotti P, Chiphangwi JD, Henderson R,
Dallabetta G, Yang LP, Hoover D. Maternal vitamin
A deficiency and child growth failure during human
immunodeficiency virus infection. J Acquir Immune
Defic Syndr Hum Retrovirol 1997;14:21922.
69. Chatterjee A, Bosch RJ, Hunter DJ, Manji K, Msamanga
GI, Fawzi WW. Vitamin A and vitamin B-12 concentrations in relation to morbidity and mortality among
children born to HIV-infected women. J Trop Pediatr
2010;56:2735.
70. John GC, Nduati RW, Mbori-Ngacha D, Overbaugh J,
Welch M, Richardson BA, Ndinya-Achola J, Bwayo J,
Krieger J, Onyango F, Kreiss JK. Genital shedding of
human immunodeficiency virus type 1 DNA during
pregnancy: association with immunosuppression,
abnormal cervical or vaginal discharge, and severe
vitamin A deficiency. J Infect Dis 1997;175:5762.
71. Nduati RW, John GC, Richardson BA, Overbaugh
J, Welch M, Ndinya-Achola J, Moses S, Holmes K,
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
S339
mothers. Eur J Clin Nutr 2005;59:12508.
85. Kupka R, Garland M, Msamanga G, Spiegelman D,
Hunter D, Fawzi W. Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J
Acquir Immune Defic Syndr 2005;39:20310.
86. Baeten JM, Mostad SB, Hughes MP, Overbaugh J,
Bankson DD, Mandaliya K, Ndinya-Achola JO, Bwayo
JJ, Kreiss JK. Selenium deficiency is associated with
shedding of HIV-1-infected cells in the female genital
tract. J Acquir Immune Defic Syndr 2001;26:3604.
87. Shor-Posner G, Miguez MJ, Pineda LM, Rodriguez A,
Ruiz P, Castillo G, Burbano X, Lecusay R, Baum M.
Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1-infected drug users during
the era of highly active antiretroviral therapy. J Acquir
Immune Defic Syndr 2002;29:16973.
88. Chariot P, Dubreuil-Lemaire ML, Zhou JY, Lamia B,
Dume L, Larcher B, Monnet I, Levy Y, Astier A, Gherardi R. Muscle involvement in human immunodeficiency virus-infected patients is associated with marked
selenium deficiency. Muscle Nerve 1997;20:3859.
89. Serwadda D, Mugerwa RD, Sewankambo NK, Lwegaba
A, Carswell JW, Kirya GB, Bayley AC, Downing RG,
Tedder RS, Clayden SA, Dalgleish AG. Slim disease: a
new disease in Uganda and its association with HTLVIII infection. Lancet 1985;2:84952.
90. Wheeler DA, Gibert CL, Launer CA, Muurahainen N,
Elion RA, Abrams DI, Bartsch GE. Weight loss as a
predictor of survival and disease progression in HIV
infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr
Hum Retrovirol 1998;18:805.
91. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen
E, Gorbach SL. Weight loss and survival in HIV-positive
patients in the era of highly active antiretroviral therapy.
J Acquir Immune Defic Syndr 2002;31:2306.
92. Jerene D, Endale A, Hailu Y, Lindtjrn B. Predictors of
early death in a cohort of Ethiopian patients treated with
HAART. BMC Infect Dis 2006;6:136.
93. Malvy E, Thiebaut R, Marimoutou C, Dabis F. Weight
loss and body mass index as predictors of HIV disease
progression to AIDS in adults. Aquitaine cohort, France,
19851997. J Am Coll Nutr 2001;20:60915
94. Mangili A, Murman DH, Zampini AM, Wanke CA.
Nutrition and HIV infection: review of weight loss and
wasting in the era of highly active antiretroviral therapy
from the nutrition for healthy living cohort. Clin Infect
Dis 2006;42:83642.
95. Severe P, Leger P, Charles M, Noel F, Bonhomme G,
Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R,
Johnson WD Jr, Pape JW, Fitzgerald DW. Antiretroviral
therapy in a thousand patients with AIDS in Haiti. N
Engl J Med 2005;353:232534.
96. Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact
of malnutrition on survival and CD4 count response in
HIV-infected patients starting antiretroviral therapy.
HIV Med 2006;7:32330.
97. van der Sande MA, Schim van der Loeff MF, Aveika
AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A,
Corrah T, Whittle HC. Body mass index at time of HIV
diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004;37:128894.
98. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D,
S340
Gorbach SL. Weight loss and wasting remain common
complications in individuals infected with human
immunodeficiency virus in the era of highly active
antiretroviral therapy. Clin Infect Dis 2000;31:8035.
99. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke
C. Increasing risk of 5% or greater unintentional weight
loss in a cohort of HIV-infected patients, 1995 to 2003.
J Acquir Immune Defic Syndr 2005;40:706.
100. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani
O, Arnould L, Makombe S, Harries AD. Risk factors
for high early mortality in patients on antiretroviral
treatment in a rural district of Malawi. AIDS 2006;
20:235560.
101. Schwenk A, Beisenherz A, Romer K, Kremer G,
Salzberger B, Elia M. Phase angle from bioelectrical
impedance analysis remains an independent predictive
marker in HIV-infected patients in the era of highly
active antiretroviral treatment. Am J Clin Nutr 2000;
72:496501.
102. Kotler DP, Tierney AR, Wang J, Pierson RNJ. Magnitude
of body-cell-mass depletion and the timing of death
from wasting in AIDS. Am J Clin Nutr 1989;50:4447.
103. Babameto G, Kotler DP. Malnutrition in HIV infection.
Gastroenterol Clin North Am 1997;26:393415.
104. Wanke C, Kotler D. The approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr
2004;37:S2848.
105. Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S,
Mayer K, Wanke C. Weight and body shape change in a
treatment-nave population after 6 months of nevirapine-based generic highly active antiretroviral therapy in
South India. Clin Infect Dis 2007;44:295300.
106. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P,
Feingold KR. Resting energy expenditure, caloric intake,
and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55:45560.
107. Grunfeld C. What causes wasting in AIDS? N Engl J
Med 1995;333:1234.
108. Macallan DC, Noble C, Baldwin C, Foskett M, McManus
T, Griffin GE. Prospective analysis of patterns of weight
change in stage IV human immunodeficiency virus
infection. Am J Clin Nutr 1993;58:41726.
109. Macallan DC. Wasting in HIV infection and AIDS. J
Nutr 1999;129:238S42S.
110. Macallan DC. Nutrition and immune function in
human immunodeficiency virus infection. Proc Nutr
Soc 1999;58:7438.
111. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice
AM, Coward WA, Sawyer MB, McManus TJ, Griffin GE.
Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:838.
112. Young J. HIV and medical nutrition therapy. J Am Diet
Assoc 1997;10:S1617.
113. Grinspoon S, Mulligan K. Weight loss and wasting in
patients infected with human immunodeficiency virus.
Clin Infect Dis 2003;36:S6978.
114. Villamor E, Manji K, Fawzi WW. Human Immunodeficiency virus infection. In: Semba RD, Bloem MW, eds.
Nutrition and health in developing countries, 2nd ed.
Totowa, NJ, USA: Humana Press, 2008:30739.
115. Michaelsen KF, Hoppe C, Roos N, Kaestel P, Stougaard
M, Lauritzen L, Mlgaard C, Girma T, Friis H. Choice
Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Vitamin A supplementation and human immunodeficiency virus type
1 shedding in women: results of a randomized clinical
trial. J Infect Dis 2002;185:118791.
127. Alpha-Tocopherol, Beta Carotene Cancer Prevention
Study Group. The effect of vitamin E and carotene on
the incidence of lung cancer and other cancers in male
smokers. N Engl J Med 1994;330:102935.
128. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards
BK, Rautalahti M, Hartman AM, Palmgren J, Freedman
LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala
E, Liippo K, Salomaa ER, Tangrea JA, Teppo L, Askin
FB, Taskinen E, Erozan Y, Greenwald P, Huttunen
JK. -Tocopherol and -carotene supplements and
lung cancer incidence in the Alpha-Tocopherol, BetaCarotene Cancer Prevention Study: effects of base-line
characteristics and study compliance. J Natl Cancer Inst
1996;88:156070.
129. Trnwall ME, Virtamo J, Korhonen PA, Virtanen
MJ, Taylor PR, Albanes D, Huttunen JK. Effect of
-tocopherol and -carotene supplementation on coronary heart disease during the 6-year post-trial follow-up
in the ATBC study. Eur Heart J 2004;25:11718.
130. Omenn GS, Goodman GE, Thornquist MD, Balmes
J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects
of a combination of beta carotene and vitamin A on
lung cancer and cardiovascular disease. N Engl J Med
1996;334:11505.
131. Palozza P. Prooxidant actions of carotenoids in biologic
systems. Nutr Rev 1998;56:25765.
132. McGill CR, Green NR, Meadows MC, Gropper SS.
Beta-carotene supplementation decreases leukocyte
superoxide dismutase activity and serum glutathione
peroxidase concentration in humans. J Nutr Biochem
2003;14:65662.
133. Siems W, Wiswedel I, Salerno C, Crif C, Augustin W,
Schild L, Langhans CD, Sommerburg O. -Carotene
breakdown products may impair mitochondrial functions potential side effects of high-dose -carotene
supplementation. J Nutr Biochem 2005;16:38597.
134. Coodley GO, Coodley MK, Lusk R, Green TR, Bakke
AC, Wilson D, Wachenheim D, Sexton G, Salveson C.
Beta-carotene in HIV infection: an extended evaluation.
AIDS 1996;10:96773.
135. Nimmagadda AP, Burri BJ, Neidlinger T, OBrien WA,
Goetz MB. Effect of oral beta-carotene supplementation
on plasma human immunodeficiency virus (HIV) RNA
levels and CD4+ cell counts in HIV-infected patients.
Clin Infect Dis 1998;27:13113.
136. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia
HM. Randomized trial testing the effect of vitamin A
supplementation on pregnancy outcomes and early
mother-to-child HIV-1 transmission in Durban, South
Africa. South African Vitamin A Study Group. AIDS
1999;13:151724.
137. Fawzi WW, Msamanga GI, Hunter D, Renjifo B, Antelman G, Bang H, Manji K, Kapiga S, Mwakagile D,
Essex M, Spiegelman D. Randomized trial of vitamin
supplements in relation to transmission of HIV-1
through breastfeeding and early child mortality. AIDS
2002;16:193544.
138. Fawzi W, Msamanga G, Antelman G, Xu C, Hertzmark
S341
E, Spiegelman D, Hunter D, Anderson D. Effect of prenatal vitamin supplementation on lower-genital levels
of HIV type 1 and interleukin type 1 beta at 36 weeks of
gestation. Clin Infect Dis 2004;38:71622.
139. Austin J, Singhal N, Voigt R, Smaill F, Gill MJ, Walmsley
S, Salit I, Gilmour J, Schlech WF 3rd, Choudhri S, Rachlis A, Cohen J, Trottier S, Toma E, Phillips P, Ford PM,
Woods R, Singer J, Zarowny DP, Cameron DW; CTN
091/CRIT Cartenoids Study Group. A community randomized controlled clinical trial of mixed carotenoids
and micronutrient supplementation of patients with
acquired immunodeficiency syndrome. Eur J Clin Nutr
2006;60:126676.
140. Spada C, Treitinger A, Reis M, Masokawa IY, Verdi
JC, Luiz MC, Silveira MV, Oliveira OV, Michelon CM,
Avila-Jnior S, Gil DO, Ostrowsky S. An evaluation of
antiretroviral therapy associated with alpha-tocopherol
supplementation in HIV-infected patients. Clin Chem
Lab Med 2002;40:4569.
141. de Souza Jnior O, Treitinger A, Baggio GL, Michelon
C, Verdi JC, Cunha J, Ferreira SI, Spada C. Alphatocopherol as an antiretroviral therapy supplement
for HIV-1-infected patients for increased lymphocyte
viability. Clin Chem Lab Med 2005;3:37682.
142. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit
IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected
subjects. AIDS 1998;12:16539.
143. Jaruga P, Jaruga B, Gackowski D, Olczak A, Halota W,
Pawlowska M, Olinski R. Supplementation with antioxidant vitamins prevents oxidative modification of DNA
in lymphocytes of HIV-infected patients. Free Radic Biol
Med 2002;32:41420.
144. McComsey G, Southwell H, Gripshover B, Salata R,
Valdez H. Effect of antioxidants on glucose metabolism
and plasma lipids in HIV-infected subjects with lipoatrophy. J Acquir Immune Defic Syndr 2004;33:6057.
145. Delmas-Beauvieux MC, Peuchant E, Couchouron A,
Constans J, Sergeant C, Simonoff M, Pellegrin JL, Leng
B, Conri C, Clerc M. The enzymatic antioxidant system
in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Am J Clin
Nutr 1996;64:1017.
146. Look MP, Rockstroh JK, Rao GS, Barton S, Lemoch H,
Kaiser R, Kupfer B, Sudhop T, Spengler U, Sauerbruch T.
Sodium selenite and N-acetylcysteine in antiretroviralnaive HIV-1-infected patients: a randomized, controlled
pilot study. Eur J Clin Invest 1998;28:38997.
147. Burbano X, Miguez-Burbano MJ, McCollister K, Zhang
G, Rodriguez A, Ruiz P, Lecusay R, Shor-Posner G.
Impact of a selenium chemoprevention clinical trial on
hospital admissions of HIV-infected participants. HIV
Clin Trials 2002;3:48391.
148. Hurwitz BE, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, ShorPosner G, Skyler JS, Schneiderman N. Suppression of
human immunodeficiency virus type 1 viral load with
selenium supplementation: a randomized controlled
trial. Arch Intern Med 2007;167:14854.
149. Ross DA, Cousens S, Wedner SH, Sismanidis C. Does
selenium supplementation slow progression of HIV?
Potentially misleading presentation of the results of a
S342
trial. Arch Intern Med 2007;167:15556.
150. Passaretti C, Gupta A. Selenium and HIV-1: hype or
hope? Arch Intern Med 2007;167:25301.
151. Dillon DM, Stapleton JT. Selenium effects on
HIV RNA and CD4 cell counts. Arch Intern Med
2007;67:15567.
152. Kupka R, Mugusi F, Aboud S, Msamanga GI, Finkelstein
JL, Spiegelman D, Fawzi WW. Randomized, doubleblind, placebo-controlled trial of selenium supplements
among HIV-infected pregnant women in Tanzania:
effects on maternal and child outcomes. Am J Clin Nutr
2008;87:18028.
153. Kupka R, Mugusi F, Aboud S, Hertzmark E, Spiegelman
D, Fawzi WW. Effect of selenium supplements on hemoglobin concentration and morbidity among HIV-1-infected Tanzanian women. Clin Infect Dis 2009;48:14758.
154. Fawzi WW, Villamor E, Msamanga GI, Antelman G,
Aboud S, Urassa W, Hunter D. A trial of zinc supplements in relation to pregnancy outcomes, hematologic
indicators, and T-cell counts among HIV-1 infected
women in Tanzania. Am J Clin Nutr 2005;81:1617.
155. Villamor E, Aboud S, Koulinska IN, Kupka R, Urassa W,
Chaplin B, Msamanga G, Fawzi WW. Zinc supplementation to HIV-1-infected pregnant women: effects on
maternal anthropometry, viral load, and early motherto-child transmission. Eur J Clin Nutr 2006;60:8629.
156. Crcamo C, Hooton T, Weiss NS, Gilman R, Wener MH,
Chavez V, Meneses R, Echevarria J, Vidal M, Holmes
KK. Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV-1 infection. J Acquir Immune Defic Syndr 2006;43:197201.
157. Deloria-Knoll M, Steinhoff M, Semba RD, Nelson K,
Vlahov D, Meinert CL. Effect of zinc and vitamin A supplementation on antibody responses to a pneumococcal
conjugate vaccine in HIV-positive injection drug users:
a randomized trial. Vaccine 2006;24:16709.
158. Clark TD, Semba RD. Iron supplementation during
human immunodeficiency virus infection: a doubleedged sword? Med Hypotheses 2001;57:4769.
159. Olsen A, Mwaniki D, Krarup H, Friis H. Low-dose iron
supplementation does not increase HIV-1 load. J Acquir
Immune Defic Syndr 2004;36:6378.
160. Semba RD, Ricketts EP, Mehta S, Netski D, Thomas D,
Kirk G, Wu AW, Vlahov D. Effect of micronutrients
and iron supplementation on hemoglobin, iron status,
and plasma hepatitis C and HIV RNA levels in female
injection drug users: a controlled clinical trial. J Acquir
Immune Defic Syndr 2007;45:298303.
161. Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ,
McGrath N, Mwakagile D, Antelman G, Mbise R, Herrera G, Kapiga S, Willett W, Hunter DJ. Randomised
trial of effects of vitamin supplements on pregnancy
outcomes and T cell counts in HIV-1-infected women
in Tanzania. Lancet 1998;351:147782.
162. Villamor E, Msamanga G, Spiegelman D, Antelman G,
Peterson KE, Hunter DJ, Fawzi WW. Effect of multivitamin and vitamin A supplements on weight gain during
pregnancy among HIV-1-infected women. Am J Clin
Nutr 2002;76:108290.
163. Fawzi WW, Msamanga G, Hunter D, Urassa E, Renjifo B,
Mwakagile D, Hertzmark E, Coley J, Garland M, Kapiga
S, Antelman G, Essex M, Spiegelman D. Randomized
trial of vitamin supplements in relation to vertical
S343
people living with HIV/AIDS. Report of a technical
consultation. Geneva: WHO, 2003.
191. World Health Organization. Management of severe
malnutrition. A manual for physicians and other senior
health workers. Geneva: WHO, 1999.
192. World Health Organization. Department of Nutrition
for Health and Development. Executive summary of a
scientific review. Consultation on nutrition and HIV/
AIDS in Africa: evidence, lessons and recommendations for action. Durban, South Africa 1013 April 2005.
Available from: http://www.who.int/entity/nutrition/
topics/Executive%20Summary%20WHO.pdf. Accessed
14 September 2010.
193. Food and Nutrition Technical Assistance. HIV/AIDS: a
guide for nutritional care and support, 2nd ed. Washington, DC: FANTA, Academy for Educational Development, 2004.
194. Department of Health. Directorate: Nutrition. National
guidelines on nutrition for people living with HIV,
AIDS, TB and other chronic debilitating conditions. Pretoria, South Africa: Department of Health, 2006:177.
195. Hsu JW-C, Pencharz PB, Macallan D, Tomkins A.
Macronutrients and HIV/AIDS: a review of current
evidence. Consultation on Nutrition and HIV/AIDS
in Africa: evidence, lessons and recommendations
for action. Durban, South Africa, 1013 April 2005.
Geneva, World Health Organization. Available from
http://www.who.int/entity/nutrition/topics/Paper%20
Number%201%20-%20Macronutrients.pdf . Accessed
14 September 2010.
196. Ndekha M, van Oosterhout JJ, Zijlstra E, Manary M,
Saloojee H, Manary M. Supplementary feeding with
either ready-to-use fortified spread or corn-soy blend in
wasted adults starting antiretroviral therapy in Malawi:
randomized investigator blinded, controlled trial. BMJ
2009;338:b1867.
197. Bahwere P, Sadler K, Collins S. Acceptability and
effectiveness of chickpea sesame-based ready-to-use
therapeutic food in malnourished HIV-positive adults.
Patient Prefer Adherence 2009;3:6775.
198. Dibari F. A qualitative investigation of Plumpynut
consumption and access in adults enrolled in an MoH/
MSF HIV programme in Kenya. 2008. Available at:
http://www.validinternational.org/demo/reports//
HIV/080515%20MSF%20-%20abstract.pdf. Accessed
19 August 2010.
199. Golden MH. Proposed recommended nutrient densities
for moderately malnourished children. Food Nutr Bull
2009;30:S267343.
200. Mahlungulu SSN, Grobler L, Visser MME, Volmink J.
Nutritional interventions for reducing morbidity and
mortality in people with HIV. Cochrane Database Syst
Rev 2007;3:CD004536.
201. Academy of Sciences of South Africa (ASSAf). HIV/
AIDS, TB and nutrition. Scientific inquiry into the
nutritional influences on human immunity with special reference to HIV infection and active TB in South
Africa. 2007. ASSAf, Pretoria, South Africa. Available
at: www.assaf.org.za. Accessed 19 August 2010.
202. Karsegard VL, Raguso CA, Genton L, Hirschel B,
Pichard C. L-Ornithine alpha-ketoglutarate in HIV
infection: effects of muscle, gastrointestinal, and
immune functions. Nutrition 2004;20:51520.
S344
203. Shabert JK, Winslow C, Lacey JM, Wilmore DW.
Glutamine-antioxidant supplementation increases
body cell mass in AIDS patients with weight loss: a
randomized, double-blind controlled trial. Nutrition
1999;15:8604.
204. Koethe JR, Chi BH, Megazinni KM, Heimburger DC,
Stringer JSA. Macronutrient supplementation for malnourished HIV-infected adults: a review of the evidence
in resource-adequate and resource-constrained settings.
Clin Infect Dis 2009;49:78798.
205. Cantrell RA, Sinkala M, Megazinni K, Lawson-Marriott
S, Washington S, Chi BH, Tambatamba-Chapula B, Levy
J, Stringer EM, Mulenga L, Stringer JS. A pilot study of
food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka,
Zambia. J Acquir Immune Defic Syndr 2008;49:1905.
206. de Pee S, Bloem MW. Current and potential role of
specially formulated foods and food supplements for
preventing malnutrition among 623 months old and
treating moderate malnutrition among 659 months
old children. Background paper prepared for WHO
UNICEF WFP UNHCR informal consultation on the
management of moderate malnutrition in under-5
children. Food Nutr Bull 2009;30:S43463.
207. Ndekha M, van Oosterhout JJG, Saloojee H, Pettifor J,